Breastfeeding already increases fluid requirements substantially
Anti-oxidant and anti-aging benefits
[153] Also in October 2020, Lilly announced that the National Institutes of Health (NIH) ACTIV-3 clinical trial evaluating its monoclonal antibody, bamlanivimab (LYCoV555), found that bamlanivimab was not effective in treating people hospitalized with COVID-19, [154] but data showed bamlanivimab might be effective in treating COVID-19 by reducing viral load, symptoms, and the risk of hospitalization in outpatients
Aside from their primary applications, both MT1 and MT2 have shown potential in various secondary benefits, such as regulating blood pressure, influencing central nervous system functions, and enhancing willpower
Convenient daily intake, easily added to beverages or shakes
For personalized dosage recommendations, consult a healthcare provider